SAN FRANCISCO — RGX-314 gene therapy demonstrated meaningful reductions in anti-VEGF injections and increases in visual acuity and central retinal thickness among patients with wet age-related macular degeneration, according to an update presented at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.
“RGX-314 utilizes a proprietary gene delivery platform that is hypothesized to deliver longer and higher protein expression with a lower immune response,” Jeffrey S. Heier, MD, co-president and director of retina research at Ophthalmic Consultants of
Uncategorized